AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose ABCL635 significantly improved sleep and patient global impression of change ABCL635 demonstrated a favorable tolerability profile AbCellera to host a conference call and live webcast today at 4:30 a.m. PT / 7:30 a.m. ET VANCOUVER, British […]
AbCellera, a company listed on the Nasdaq under the ticker ABCL, has reported positive top-line results from the Phase 2 clinical trial of ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. This antibody is being developed as a non-hormonal, long-acting, subcutaneous treatment for moderate-to-severe vasomotor symptoms (VMS M-S), commonly known as hot flashes, experienced by menopausal women.
The trial met its primary efficacy endpoints by demonstrating statistically significant reductions in both the frequency and severity of VMS M-S at week 4, compared to the placebo group, following a single dose. Additionally, ABCL635 was observed to significantly improve sleep quality and overall patient perception of improvement, as measured by the patient global impression of change (PGI-C).
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
